Logo

HUTCHMED Reports NDA Acceptance with Priority Review by the NMPA for Sovleplenib to Treat Primary Immune Thrombocytopenia (PIT)

Share this
HUTCHMED

HUTCHMED Reports NDA Acceptance with Priority Review by the NMPA for Sovleplenib to Treat Primary Immune Thrombocytopenia (PIT)

Shots:

  • The NDA was submitted based on data from the P-III (ESLIM-01) clinical trial evaluating the safety & efficacy of Sovleplenib vs PBO in patients (n=188) with primary ITP
  • As per the results the study met its 1EP by depicting a clinically meaningful & statistically significant increase in DRR in patients treated with Sovleplenib vs PBO. Moreover, the 2EPs of response rate & safety were also met
  • Sovleplenib is a selective inhibitor of Syk, a major component in B-cell receptor & FcR signalling & is a target for the treatment of multiple subtypes of B-cell lymphomas & autoimmune disorders

Ref: HUTCHMED | Image: HUTCHMED

Related News:- HUTCHMED Reports P-III Trial (ESLIM-01) Results of Sovleplenib for Primary Immune Thrombocytopenia in China

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions